AKYA Stock Overview
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research.
Akoya Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.47|
|52 Week High||US$23.44|
|52 Week Low||US$8.02|
|1 Month Change||-14.22%|
|3 Month Change||-17.65%|
|1 Year Change||-56.18%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-63.65%|
Recent News & Updates
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
There's been a notable change in appetite for Akoya Biosciences, Inc. ( NASDAQ:AKYA ) shares in the week since its...
|AKYA||US Life Sciences||US Market|
Return vs Industry: AKYA underperformed the US Life Sciences industry which returned -9.4% over the past year.
Return vs Market: AKYA underperformed the US Market which returned -11.5% over the past year.
|AKYA Average Weekly Movement||12.7%|
|Life Sciences Industry Average Movement||10.9%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: AKYA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AKYA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. It offers single-cell resolution with spatial context that provides a wealth of information to visualize tissue organization and disease pathology on a molecular level to understand disease progression and treatment response. The company also provides PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen, or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Akoya Biosciences Fundamentals Summary
|AKYA fundamental statistics|
Is AKYA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AKYA income statement (TTM)|
|Cost of Revenue||US$22.69m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.36|
|Net Profit Margin||-85.91%|
How did AKYA perform over the long term?See historical performance and comparison
Is Akoya Biosciences undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AKYA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AKYA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: AKYA is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: AKYA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AKYA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AKYA is overvalued based on its PB Ratio (3.3x) compared to the US Life Sciences industry average (2x).
How is Akoya Biosciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AKYA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AKYA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AKYA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AKYA's revenue (21.2% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: AKYA's revenue (21.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AKYA is forecast to be unprofitable in 3 years.
How has Akoya Biosciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AKYA is currently unprofitable.
Growing Profit Margin: AKYA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AKYA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AKYA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKYA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).
Return on Equity
High ROE: AKYA has a negative Return on Equity (-48.1%), as it is currently unprofitable.
How is Akoya Biosciences's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AKYA's short term assets ($126.5M) exceed its short term liabilities ($31.7M).
Long Term Liabilities: AKYA's short term assets ($126.5M) exceed its long term liabilities ($48.8M).
Debt to Equity History and Analysis
Debt Level: AKYA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if AKYA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKYA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AKYA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 62.3% each year.
What is Akoya Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AKYA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AKYA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AKYA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKYA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AKYA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brian McKelligon (52 yo)
Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...
CEO Compensation Analysis
Compensation vs Market: Brian's total compensation ($USD2.27M) is about average for companies of similar size in the US market ($USD2.59M).
Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.
Experienced Management: AKYA's management team is considered experienced (3.8 years average tenure).
Experienced Board: AKYA's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Akoya Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Akoya Biosciences, Inc.
- Ticker: AKYA
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$333.795m
- Shares outstanding: 37.59m
- Website: https://www.akoyabio.com
Number of Employees
- Akoya Biosciences, Inc.
- 100 Campus Drive
- 6th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.